Sherbrooke Park Advisers’s Pulmonx LUNG Stock Holding History

Sherbrooke Park Advisers’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,494	Closed	-$104K	–	663
2025 Q1	$104K	Buy	+15,494	New	+$110K	0.05%	505

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Sherbrooke Park Advisers's LUNG Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Pulmonx (LUNG) in Q2 2025, closing a stake of 15,494 shares — an estimated $104K sold.

Sherbrooke Park Advisers first reported a position in LUNG in Q1 2025 and held it in 1 quarter. The position peaked at $104K in Q1 2025. 113 funds tracked by Wall St. Rank hold LUNG as of Q2 2025.

Sherbrooke Park Advisers reported no remaining Pulmonx position as of Q2 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 15,494 Pulmonx shares in Q2 2025, an estimated $104K.
Sherbrooke Park Advisers first reported a position in Pulmonx in Q1 2025 and held it in 1 quarter.
Sherbrooke Park Advisers's Pulmonx position peaked at $104K in Q1 2025.
113 funds tracked by Wall St. Rank held Pulmonx as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.